Arbutus Biopharma Corp (NAS:ABUS)

$ 4.43 0.12 (2.78%) Market Cap: 837.25 Mil Enterprise Value: 675.15 Mil PE Ratio: 0 PB Ratio: 6.82 GF Score: 50/100

Q2 2024 Arbutus Biopharma Corp Earnings Call Transcript
Aug 01, 2024

$3.81 (+1.06%)

Earnings
Q1 2024 Arbutus Biopharma Corp Earnings Call Transcript
May 02, 2024

$2.68 (-0.37%)

Earnings
Q4 2023 Arbutus Biopharma Corp Earnings Call Transcript
Feb 29, 2024

$2.8 (-2.78%)

Earnings
Q3 2023 Arbutus Biopharma Corp Earnings Call Transcript
Nov 07, 2023

$1.85 (-1.60%)

Earnings
Q2 2023 Arbutus Biopharma Corp Earnings Call Transcript
Aug 03, 2023

$2.06 (-0.96%)

Earnings
Arbutus Biopharma Corp at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Q1 2023 Arbutus Biopharma Corp Earnings Call Transcript
May 04, 2023

$2.55 (+1.59%)

Earnings
Q4 2022 Arbutus Biopharma Corp Earnings Call Transcript
Mar 02, 2023

$2.81

Earnings
Q3 2022 Arbutus Biopharma Corp Earnings Call Transcript
Nov 09, 2022

$2.44 (-0.81%)

Earnings
Arbutus Biopharma Corp AASLD Call Transcript
Nov 04, 2022
Q2 2022 Arbutus Biopharma Corp Earnings Call Transcript
Aug 04, 2022

$2.54 (+3.25%)

Earnings
Arbutus Biopharma Corp to Discuss New Data at EASL ILC 2022 Transcript
Jun 27, 2022
Arbutus Biopharma Corp at JMP Securities Life Sciences Conference (Virtual) Transcript
Jun 15, 2022
Q1 2022 Arbutus Biopharma Corp Earnings Call Transcript
May 05, 2022

$2.55 (+2.41%)

Earnings
Q4 2021 Arbutus Biopharma Corp Earnings Call Transcript
Mar 03, 2022

$2.95 (-4.53%)

Earnings
Q3 2021 Arbutus Biopharma Corp Earnings Call Transcript
Nov 04, 2021

$3.88 (+0.78%)

Earnings
Arbutus Biopharma Corp at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
Arbutus Biopharma Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Arbutus Biopharma Corp Earnings Call Transcript
Aug 05, 2021

$3.04 (+10.14%)

Earnings
Arbutus Biopharma Corp to Discuss the New Data Being Presented at EASL - Conference Call Transcript
Jun 28, 2021
Arbutus Biopharma Corp at JMP Securities Life Sciences Virtual Conference Transcript
Jun 17, 2021
Arbutus Biopharma Corp Annual Shareholders Meeting Transcript
May 26, 2021
Q1 2021 Arbutus Biopharma Corp Earnings Call Transcript
May 05, 2021

$2.96 (-11.11%)

Earnings
Q4 2020 Arbutus Biopharma Corp Earnings Call Transcript
Mar 04, 2021

$3.14 (-13.74%)

Earnings
Arbutus Biopharma Corp to Provide an AB-729 Clinical Update - Conference Call Transcript
Nov 16, 2020
Q3 2020 Arbutus Biopharma Corp Earnings Call Transcript
Nov 05, 2020

$2.87 (-6.21%)

Earnings
Q2 2020 Arbutus Biopharma Corp Earnings Call Transcript
Aug 07, 2020

$3.8 (-13.04%)

Earnings
Arbutus Biopharma Corp Annual Shareholders Meeting Transcript
May 28, 2020
Arbutus Biopharma Corp at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Arbutus Biopharma Corp AB-729 Clinical Update Conference Call Transcript
May 18, 2020
Q1 2020 Arbutus Biopharma Corp Earnings Call Transcript
May 11, 2020

$1.44 (+6.67%)

Earnings
Arbutus Biopharma Corp to Discuss the Preliminary Phase 1a/1b Clinical Trial Results for AB-729 Conference Call Transcript
Mar 26, 2020
Q4 2019 Arbutus Biopharma Corp Earnings Call Transcript
Mar 05, 2020

$3 (-0.99%)

Earnings
Q3 2019 Arbutus Biopharma Corp Earnings Call Transcript
Nov 06, 2019

$1.45 (-2.68%)

Earnings
Q2 2019 Arbutus Biopharma Corp Earnings Call Transcript
Aug 05, 2019

$1.6 (-1.84%)

Earnings
Arbutus Biopharma Corp to Discuss Preliminary Phase 1a/1b Clinical Trial Results for AB-506 - Call Transcript
Jul 15, 2019
Arbutus Biopharma Corp at JMP Securities Life Science Conference Transcript
Jun 20, 2019
Arbutus Biopharma Corp at UBS Global Healthcare Conference Transcript
May 20, 2019
Q1 2019 Arbutus Biopharma Corp Earnings Call Transcript
May 06, 2019

$2.63 (+0.77%)

Earnings
Q4 2018 Arbutus Biopharma Corp Earnings Call Transcript
Mar 07, 2019

$4.02

Earnings

Arbutus Biopharma Corp to Provide an AB-729 Clinical Update - Conference Call Transcript

Nov 16, 2020 / 01:00PM GMT

Release Date Price: $3.63

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the AB-729 clinical update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Pam Murphy. Please go ahead, ma'am.

Pam Murphy

Arbutus Biopharma Corporation - IR Consultant

Good morning, and hopefully, everyone has been able to connect to the AB-729 clinical update webcast and you are able to access the slides. The slides are also available in PDF form under the Investors section of Arbutus' website at www.arbutusbio.com.

On the call today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. Bill will begin with a quick summary of the data followed by Gaston, who will walk you through the positive clinical data for 7

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.